Search
Search
About
Log in
Join
Experiences with
Idarucizumab
Posts
Communities
4 public posts
Filter results
News on antidote for Xarelto (Rivaroxaban)
Last month, the FDA gave full approval to
idarucizumab
(Praxbind, Boehringer Ingelheim) to reverse the anticoagulant effect of dabigatran (Pradaxa, Boehringer Ingelheim), a direct thrombin inhibitor, in the event of urgent surgery or life-threatening or uncontrolled bleeding."
Last month, the FDA gave full approval to
idarucizumab
(Praxbind, Boehringer Ingelheim) to reverse the anticoagulant effect of dabigatran (Pradaxa, Boehringer Ingelheim), a direct thrombin inhibitor, in the event of urgent surgery or life-threatening or uncontrolled bleeding."
MillaZ
in
Anticoagulation Support
6 years ago
Uncontrolled bleeding events with Ibrutinib and in general
Pradaxa has a special FDA approved drug Praxbind (
Idarucizumab
) but the FDA refused to approve the reversal drug AndexXA designed for the 3 Factor Xa drugs. Platelets are not the only concern regarding potential bleeding events as there are many clotting factors to consider as well.
Pradaxa has a special FDA approved drug Praxbind (
Idarucizumab
) but the FDA refused to approve the reversal drug AndexXA designed for the 3 Factor Xa drugs. Platelets are not the only concern regarding potential bleeding events as there are many clotting factors to consider as well.
ThreeWs
in
CLL Support
8 years ago
Reversal drug for those on Dabigatran.
Idarucizumab
(Praxbind) is a monoclonal antibody that reverses the anticoagulant effect of dabigatran (Pradaxa) in patients who require emergency surgery or have life-threatening bleeding. This was news today in Oz.
Idarucizumab
(Praxbind) is a monoclonal antibody that reverses the anticoagulant effect of dabigatran (Pradaxa) in patients who require emergency surgery or have life-threatening bleeding. This was news today in Oz.
Ozchick
in
Hughes Syndrome APS Forum
8 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
FDA Approves Praxbind to Reverse Anticoagulant Pradaxa | October 16, 2015
The US Food and Drug Administration (FDA) has granted accelerated approval to Praxbind (
idarucizumab
, Boehringer Ingelheim) to rapidly reverse the blood-thinning effects of the anticoagulant Pradaxa (dabigatran, Boehringer Ingelheim).
The US Food and Drug Administration (FDA) has granted accelerated approval to Praxbind (
idarucizumab
, Boehringer Ingelheim) to rapidly reverse the blood-thinning effects of the anticoagulant Pradaxa (dabigatran, Boehringer Ingelheim).
EngMac
in
AF Association
9 years ago
Filter results
Clear filters
Posted in
All communities
AF Association
1 result
Anticoagulation Support
1 result
CLL Support
1 result
View top 10 communities
Sort by
Most Relevant
Newest